Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

Chemometec A/S stock

CHEMM.CO
DK0060055861
A0MS80

Price

447.80 DKK
Today +/-
-1.90 DKK
Today %
-3.12 %
P

Chemometec A/S stock price

DKK
%
Weekly
Details

Price

Overview

The Quote Chart provides detailed and dynamic insights into the Chemometec A/S stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Chemometec A/S stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Chemometec A/S stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Chemometec A/S's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Chemometec A/S Stock Price History

DateChemometec A/S Price
11/15/2024447.80 DKK
11/14/2024462.00 DKK
11/13/2024467.60 DKK
11/12/2024473.00 DKK
11/11/2024501.00 DKK
11/8/2024484.40 DKK
11/7/2024378.00 DKK
11/6/2024373.20 DKK
11/5/2024388.00 DKK
11/4/2024398.60 DKK
11/1/2024408.00 DKK
10/31/2024400.00 DKK
10/30/2024408.20 DKK
10/29/2024410.80 DKK
10/28/2024408.00 DKK
10/25/2024409.80 DKK
10/24/2024416.40 DKK
10/23/2024428.00 DKK
10/22/2024424.00 DKK
10/21/2024418.60 DKK
10/18/2024440.00 DKK

Chemometec A/S Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

Understanding Revenue, EBIT, and Income

Gain insights into Chemometec A/S, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Chemometec A/S from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Chemometec A/S’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Chemometec A/S. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Chemometec A/S’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Chemometec A/S’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Chemometec A/S’s growth potential.

Chemometec A/S Revenue, EBIT and net profit per share

DateChemometec A/S RevenueChemometec A/S EBITChemometec A/S Net Income
2027e590.19 M DKK252.35 M DKK209.72 M DKK
2026e542.81 M DKK245.14 M DKK197.62 M DKK
2025e472.77 M DKK213.21 M DKK171.09 M DKK
2024407.87 M DKK168.96 M DKK136.28 M DKK
2023444.4 M DKK230.64 M DKK178.67 M DKK
2022428.39 M DKK202.76 M DKK159.47 M DKK
2021281.13 M DKK116.85 M DKK88.35 M DKK
2020214.1 M DKK77.18 M DKK59.16 M DKK
2019175.51 M DKK54.03 M DKK41.85 M DKK
2018112.69 M DKK24.28 M DKK18.22 M DKK
201790.33 M DKK10.42 M DKK7.49 M DKK
201685.23 M DKK15.9 M DKK10.48 M DKK
201561.24 M DKK5.83 M DKK7.95 M DKK
201445.2 M DKK1.6 M DKK1.2 M DKK
201341.4 M DKK1.5 M DKK300,000 DKK
201239.2 M DKK-11.5 M DKK-9.9 M DKK
201137.2 M DKK800,000 DKK100,000 DKK
201032.6 M DKK-1.6 M DKK-3.7 M DKK
200932.1 M DKK2.1 M DKK4.6 M DKK
200844.8 M DKK14.8 M DKK13.2 M DKK
200722.3 M DKK1.4 M DKK1.1 M DKK
200614.6 M DKK800,000 DKK4.1 M DKK
200513.9 M DKK100,000 DKK-1 M DKK

Chemometec A/S Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M DKK)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M DKK)NET INCOME (M DKK)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
200520062007200820092010201120122013201420152016201720182019202020212022202320242025e2026e2027e
13142244323237394145618590112175214281428444407472542590
-7.6957.14100.00-27.27-15.635.415.139.7635.5639.345.8824.4456.2522.2931.3152.313.74-8.3315.9714.838.86
53.8557.1454.5570.4559.3865.6367.5766.6765.8564.4462.3064.7166.6770.5476.5778.5081.4979.9178.8378.8768.0159.2354.41
78123119212526272938556079134168229342350321000
-141134-30-901710718415988159178136171197209
--500.00-75.001,200.00-69.23-175.00----600.0042.86-30.00157.14127.7843.9049.1580.6811.95-23.6025.7415.206.09
171716.217.417.417.417.417.417.417.415.6715.6715.6715.5215.5616.8617.417.417.417.4000
-----------------------
Details

Keystats

Revenue and Growth

The Chemometec A/S Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Chemometec A/S is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M DKK)RECEIVABLES (M DKK)OTHER REC. (M DKK)INVENTORIES (M DKK)OTHER CURRENT LIAB. (M DKK)CURRENT ASSETS (M DKK)TANGIBLE ASSETS (M DKK)LONG-T. INVEST. (k DKK)LONG-T. REC. (M DKK)INTANGIBLE ASSETS (M DKK)GOODWILL (M DKK)OTHER NON-CURRENT ASSETS (M DKK)NON-CURRENT ASSETS (M DKK)TOTAL ASSETS (M DKK)LIABILITIESCOMMON STOCK (M DKK)ADDITIONAL PAID-IN CAPITAL (M DKK)RETAINED EARNINGS (M DKK)OTHER EQUITY (M DKK)UNREAL. GAINS/LOSSES (M DKK)EQUITY (M DKK)LIABILITIES (M DKK)PROVISIONS (M DKK)OTHER SHORT-TERM LIAB. (M DKK)SHORT-TERM DEBTS (M DKK)LONG-TERM DEBT PORTION (M DKK)SHORT-TERM REC. (M DKK)LONG-T. LIAB. (M DKK)DEFERRED TAXES (M DKK)OTHER LIAB. (M DKK)LONG-T. LIABILITIES (M DKK)DEBT (M DKK)TOTAL CAPITAL (M DKK)
20052006200720082009201020112012201320142015201620172018201920202021202220232024
                                       
0.917.825.35.411.88.97.18.79.16.910.8914.1212.49.7898.296.94150.11209.03316.57296.15
1.92.14.29.35.33.444.75.45.47.3615.0814.6217.6734.7135.4450.6465.8754.8362.26
0.10.41.3113.23.31.30.51.11.84.360.350.061.521.327.8412.013.674.916.82
2.32.84.25.56.87.97.67.97.48.16.487.5413.3116.8419.5225.1130.1166.79112.64119.5
000.200.1000000.180.430.631.011.092.931.497.583.715.08
5.223.135.231.227.223.52021.82322.229.2737.5341.0246.81154.83168.26244.36352.94492.66489.8
2.11.52.945.44.63.31.91.11.75.525.4726.4228.9438.1543.3642.574.7882.6992.05
500500600500500500600400400500843194646111111172303318281
000000000000000013.493.674.910
0.52.38.317.627.531.634.522.123.324.123.6226.2130.0538.2145.1351.3857.8867.479.6694.55
00000000000000000000
04.44.42.74.62.52.43.7334.241.150.0800005.852.650
3.18.716.224.83839.240.828.127.829.334.252.8556.667.1983.3994.85114.04152.01170.23186.88
8.331.851.45665.262.760.849.950.851.563.4790.3897.62114238.21263.12358.4504.94662.89676.67
                                       
1.31.617.417.417.417.417.417.417.417.417.417.417.417.417.417.417.417.417.417.4
00000000000000000000
-12.214.921.934.338.935.235.325.525.827.128.9539.4546.5855.23108.29159.23177.96339.78411.21478.29
0000000000000.390.3847.6526.1269.610.03104.4369.62
00000000000000000000
-10.916.539.351.756.352.652.742.943.244.546.3556.8564.3873.01173.34202.75264.98357.21533.04565.32
1.20.82.22.51.31.81.211.91.43.485.394.897.269.718.438.7117.0217.5511.09
1.51.61.21.82.93.52.72.73.13.75.815.326.018.920.1117.5221.2530.188.20
000000000000.350.2806.3720.6361.82118.4298.1284.26
00000000000000000000
1.22.22.800.60.70.70.80.80.82.64.889.911.718.81.11.451.933.523.18
3.94.66.24.34.864.64.55.85.911.8815.9421.0817.8754.9847.6893.22167.55127.498.53
14.910.75.904.14.13.42.61.80.95.2317.3511.9518.401.190.914.863.640.97
00000000000004.429.310.435.76008.45
0.40.30.1000000000.240.220.290.591.071.291.832.13.4
15.311604.14.13.42.61.80.95.2317.5912.1623.119.8912.697.966.695.7412.83
19.215.612.24.38.910.187.17.66.817.1233.5333.2440.9964.8760.36101.18174.24133.14111.36
8.332.151.55665.262.760.75050.851.363.4790.3897.62114238.22263.12366.16531.45666.18676.67
Details

Balance Sheet

Understanding the Balance Sheet

The balance sheet of Chemometec A/S provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Chemometec A/S's financial health and stability.

Assets

Chemometec A/S's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Chemometec A/S must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Chemometec A/S after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Chemometec A/S's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M DKK)DEPRECIATION (M DKK)DEFERRED TAXES (M DKK)CHANGES IN WORKING CAPITAL (M DKK)NON-CASH ITEM (M DKK)PAID INTEREST (M DKK)PAID TAXES (M DKK)NET CASH FLOW FROM OPERATING ACTIVITIES (M DKK)CAPITAL EXPENDITURES (M DKK)CASH FLOW FROM INVESTING ACTIVITIES (M DKK)CASH FLOW FROM OTHER INVESTING ACTIVITIES (k DKK)INTEREST INCOME AND EXPENSES (M DKK)NET DEBT CHANGE (M DKK)NET CHANGE IN EQUITY (M DKK)CASH FLOW FROM FINANCING ACTIVITIES (M DKK)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M DKK)TOTAL DIVIDENDS PAID (M DKK)NET CHANGE IN CASH FLOW (M DKK)FREE CASH FLOW (M DKK)SHARE-BASED COMPENSATION (M DKK)
2005200620072008200920102011201220132014201520162017201820192020202120222023
001142-10-111151510245477116202230
0101267206556551015192020
0000000000000000000
-1-1-2-14101000-11-5-6-4-6-20-27-46-96
00000000000000001114-4
0000000000021001011
00000000000001011162757
0001156787513179255872107176154
-1-2-8-11-13-9-8-6-6-7-8-29-10-16-27-26-24-55-40
-1-2-8-11-13-9-8-6-6-7-9-28-10-16-27-26-24-56-40
000000000001,0000000000
0000000000000000000
3-1-2-84000004120-60-190-1-2
020180000000-600-958318000
31816-9400000-2120-757-46-26-69-2
00000000000007011010
000000000000000-356-26-690
1167-196-2-110-220-1089-15358107
-1.93-1.86-8.94-10.321.72-3.07-12.181.17-1.454.41-12.69-0.838.9731.2445.2883.28120.94113.33
0000000000000000000

Chemometec A/S stock margins

The Chemometec A/S margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Chemometec A/S. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Chemometec A/S.
  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Chemometec A/S's sales revenue. A higher gross margin percentage indicates that the Chemometec A/S retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Chemometec A/S's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Chemometec A/S's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Chemometec A/S's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Chemometec A/S. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Chemometec A/S's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Chemometec A/S Margin History

Chemometec A/S Gross marginChemometec A/S Profit marginChemometec A/S EBIT marginChemometec A/S Profit margin
2027e78.8 %42.76 %35.53 %
2026e78.8 %45.16 %36.41 %
2025e78.8 %45.1 %36.19 %
202478.8 %41.43 %33.41 %
202378.91 %51.9 %40.2 %
202280.06 %47.33 %37.23 %
202181.78 %41.57 %31.43 %
202078.56 %36.05 %27.63 %
201976.65 %30.78 %23.84 %
201870.3 %21.55 %16.16 %
201766.47 %11.53 %8.29 %
201665.48 %18.65 %12.3 %
201563.46 %9.52 %12.98 %
201465.04 %3.54 %2.65 %
201366.43 %3.62 %0.72 %
201266.58 %-29.34 %-25.26 %
201168.82 %2.15 %0.27 %
201064.42 %-4.91 %-11.35 %
200961.99 %6.54 %14.33 %
200869.42 %33.04 %29.46 %
200756.5 %6.28 %4.93 %
200658.9 %5.48 %28.08 %
200551.08 %0.72 %-7.19 %

Chemometec A/S Stock Sales Revenue, EBIT, Earnings per Share

The Chemometec A/S earnings per share therefore indicates how much revenue Chemometec A/S has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.
  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

Revenue Per Share

Revenue per share represents the total revenue Chemometec A/S earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Chemometec A/S's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Chemometec A/S’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Chemometec A/S's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Chemometec A/S Revenue, EBIT and net profit per share

DateChemometec A/S Sales per ShareChemometec A/S EBIT per shareChemometec A/S Earnings per Share
2027e33.91 DKK0 DKK12.05 DKK
2026e31.19 DKK0 DKK11.36 DKK
2025e27.17 DKK0 DKK9.83 DKK
202423.44 DKK9.71 DKK7.83 DKK
202325.54 DKK13.25 DKK10.27 DKK
202224.62 DKK11.65 DKK9.16 DKK
202116.15 DKK6.71 DKK5.08 DKK
202012.7 DKK4.58 DKK3.51 DKK
201911.28 DKK3.47 DKK2.69 DKK
20187.26 DKK1.57 DKK1.17 DKK
20175.76 DKK0.66 DKK0.48 DKK
20165.44 DKK1.01 DKK0.67 DKK
20153.91 DKK0.37 DKK0.51 DKK
20142.6 DKK0.09 DKK0.07 DKK
20132.38 DKK0.09 DKK0.02 DKK
20122.25 DKK-0.66 DKK-0.57 DKK
20112.14 DKK0.05 DKK0.01 DKK
20101.87 DKK-0.09 DKK-0.21 DKK
20091.84 DKK0.12 DKK0.26 DKK
20082.57 DKK0.85 DKK0.76 DKK
20071.38 DKK0.09 DKK0.07 DKK
20060.86 DKK0.05 DKK0.24 DKK
20050.82 DKK0.01 DKK-0.06 DKK

Chemometec A/S business model

Chemometec A/S is an internationally active company based in Allerød, Denmark, specializing in the development and distribution of instruments and solutions for cell counting and analysis. The company was founded in 1997 by Tine Kjeldsen and Steen Søndergaard and has since had a remarkable growth story. Chemometec A/S is one of the most popular companies on Eulerpool.com.

Chemometec A/S SWOT Analysis

Strengths

Chemometec A/S has a strong reputation in the market for their innovative products and technologies.

The company has a highly skilled and knowledgeable workforce, which enables them to develop and deliver high-quality solutions.

Chemometec A/S has a wide range of product offerings, catering to various industries and customer needs.

Weaknesses

One weakness of Chemometec A/S is their reliance on a limited number of suppliers, which could result in supply chain disruptions.

The company may face challenges in scaling their production capacity to meet increasing market demand.

Chemometec A/S lacks strong brand recognition compared to some of their competitors.

Opportunities

There is a growing demand for advanced technologies in the healthcare sector, which presents an opportunity for Chemometec A/S to expand their market share.

The company can explore strategic partnerships and collaborations to leverage their expertise and access new markets.

Chemometec A/S can invest in research and development to continually innovate and develop new products that meet emerging customer needs.

Threats

Intense competition in the industry poses a threat to Chemometec A/S, as competitors may offer similar products at lower prices.

Evolving regulations and compliance requirements could impact the company's operations and increase costs.

Changes in market trends and customer preferences may require Chemometec A/S to adapt quickly in order to remain competitive.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Chemometec A/S Eulerpool Fair Value

Details

Fair Value

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Chemometec A/S historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Chemometec A/S shares outstanding

The number of shares was Chemometec A/S in 2023 — This indicates how many shares 17.402 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

Revenue Per Share

Revenue per share represents the total revenue Chemometec A/S earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Chemometec A/S's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Chemometec A/S’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Chemometec A/S's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Chemometec A/S dividend history and estimates

In 2023, Chemometec A/S paid a dividend amounting to 6 DKK. Dividend means that Chemometec A/S distributes a portion of its profits to its owners.
  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details

Dividend

Dividend Overview

The dividend per year chart for Chemometec A/S provides a comprehensive view of the annual dividends distributed to shareholders. Analyze the trend to understand the consistency and growth in dividend payouts over the years.

Interpretation and Use

A consistent or increasing trend in dividends can indicate the company's profitability and financial health. Investors can use this data to identify Chemometec A/S’s potential for long-term investment and income generation through dividends.

Investment Strategy

Incorporate the dividend data in evaluating Chemometec A/S's overall performance. A thorough analysis, considering other financial aspects, will help in making informed investment decisions for optimal capital growth and income generation.

Chemometec A/S Dividend History

DateChemometec A/S Dividend
2027e1.89 DKK
2026e1.75 DKK
2025e1.61 DKK
20244 DKK
20236 DKK
20214 DKK
202014.5 DKK
20197.5 DKK

Chemometec A/S dividend payout ratio

In 2023, Chemometec A/S had a payout ratio of 249.62%. The payout ratio indicates the percentage of the company's profits that Chemometec A/S distributes as dividends.
  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Payout ratio
Details

Payout ratio

What is Yearly Payout Ratio?

The yearly payout ratio for Chemometec A/S represents the proportion of earnings paid out as dividends to shareholders. It is an indicator of the company's financial health and stability, illustrating how much profit is being returned to investors versus being reinvested back into the company.

How to Interpret the Data

A lower payout ratio for Chemometec A/S could mean that the company is reinvesting more into its growth, whereas a higher ratio indicates more earnings are being distributed as dividends. Investors seeking regular income might prefer companies with a higher payout ratio, while those looking for growth may opt for companies with a lower ratio.

Using the Data for Investments

Evaluate Chemometec A/S's payout ratio in conjunction with other financial metrics and performance indicators. A sustainable payout ratio, coupled with strong financial health, can indicate a reliable dividend payout. However, a very high ratio might suggest the company is not sufficiently reinvesting in its future growth.

Chemometec A/S Payout Ratio History

DateChemometec A/S Payout ratio
2027e218.41 %
2026e226.21 %
2025e233.89 %
2024195.11 %
2023249.62 %
2022256.93 %
202178.79 %
2020413.16 %
2019278.86 %
2018256.93 %
2017256.93 %
2016256.93 %
2015256.93 %
2014256.93 %
2013256.93 %
2012256.93 %
2011256.93 %
2010256.93 %
2009256.93 %
2008256.93 %
2007256.93 %
2006256.93 %
2005256.93 %
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Chemometec A/S.

Eulerpool ESG Scorecard© for the Chemometec A/S stock

Eulerpool World ESG Rating (EESG©)

14/ 100

🌱 Environment

10

👫 Social

28

🏛️ Governance

5

Environment

Scope 1 - Direct Emissions
Scope 2 - Indirect emissions from purchased energy
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees42
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Chemometec A/S shareholders

%
Name
Stocks
Change
Date
14.20998 % BlackRock Investment Management (UK) Ltd.2,472,8921,602,7687/3/2024
9.99999 % Invesco Advisers, Inc.1,740,24806/30/2024
4.99999 % SEB Asset Management (Denmark)870,12406/30/2024
3.62390 % Glensbjerg (Martin)630,65006/30/2023
3.04689 % SEB Investment Management AB530,235-22,7649/30/2024
3.01681 % Swedbank Robur Fonder AB525,000-47,0009/30/2024
2.95728 % Handelsbanken Kapitalf¿rvaltning AB514,640-3,4419/30/2024
2.63848 % The Vanguard Group, Inc.459,162-4489/30/2024
2.47956 % Fidelity Management & Research Company LLC431,5063,0428/31/2024
2.27417 % Norges Bank Investment Management (NBIM)395,763-15,7036/30/2024
1
2
3
4
5
...
10

Chemometec A/S Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
SupplierCustomer0,720,640,68-0,060,40-0,76
SupplierCustomer0,500,720,770,70-0,300,32
SupplierCustomer0,450,620,35-0,060,560,56
SupplierCustomer0,440,840,31-0,010,620,64
SupplierCustomer0,410,520,09 0,400,50
SupplierCustomer-0,600,720,230,11-0,080,64
1

Most common questions regarding Chemometec A/S

What values and corporate philosophy does Chemometec A/S represent?

Chemometec A/S represents strong values and a clear corporate philosophy. The company prioritizes innovation, scientific excellence, and customer satisfaction. With a focus on providing advanced solutions for cell counting and analysis, Chemometec A/S is committed to delivering accurate, reliable, and user-friendly products. They strive to empower researchers and laboratories with cutting-edge technologies that enhance efficiency and productivity. By continuously investing in research and development, Chemometec A/S ensures that their customers have access to the latest advancements in cell analysis. With their commitment to quality and customer-centric approach, Chemometec A/S aims to be a trusted partner in the field of life sciences.

In which countries and regions is Chemometec A/S primarily present?

Chemometec A/S is primarily present in several countries and regions worldwide. The company operates in various regions, including Europe, North America, Asia-Pacific, and the Middle East. Some specific countries where Chemometec A/S has a significant presence are Denmark, the United States, China, Germany, India, Japan, and many others. With its global reach, Chemometec A/S aims to serve customers and expand its market presence across different economies.

What significant milestones has the company Chemometec A/S achieved?

Some significant milestones achieved by Chemometec A/S include the development and commercialization of their flagship product, the NucleoCounter® system, which revolutionized cell counting and viability analysis in life science research and industry. The company also expanded its product portfolio with the introduction of the NucleoCassette™ and NucleoView™ software, enhancing the efficiency and accuracy of cell analysis further. Chemometec A/S successfully established a global presence, with offices and distributors in key markets worldwide, consolidating its position as a leading provider of innovative solutions for cell analysis. Through continuous investment in research and development, the company continues to deliver groundbreaking technologies to support scientific advancements.

What is the history and background of the company Chemometec A/S?

Chemometec A/S is a Danish biotechnology company founded in 1997. With headquarters in Allerød, Denmark, the company specializes in developing and manufacturing innovative instruments and software solutions for cell counting and analysis. Chemometec A/S has established itself as a leading provider of automated cell counters, offering high-quality and reliable products to the global scientific community. The company has garnered significant recognition for its unique imaging technology and advanced image analysis algorithms. Over the years, Chemometec A/S has expanded its product portfolio, ensuring accurate cell counting and viability assessment, particularly in the fields of hematology, microbiology, and life sciences.

Who are the main competitors of Chemometec A/S in the market?

The main competitors of Chemometec A/S in the market are Beckman Coulter, Inc., Sysmex Corporation, and Becton, Dickinson and Company.

In which industries is Chemometec A/S primarily active?

Chemometec A/S is primarily active in the biotechnology and life sciences industries.

What is the business model of Chemometec A/S?

The business model of Chemometec A/S is focused on providing advanced solutions for cellular analysis and diagnostics. The company specializes in developing and manufacturing instruments that enable users to quantify and analyze cells for various purposes, such as cell counting, size measurement, viability assessment, and cell cycle analysis. Chemometec A/S's innovative technologies and products cater to a wide range of industries, including biopharmaceuticals, life sciences research, clinical diagnostics, and industrial manufacturing. With a strong emphasis on accuracy, reliability, and user-friendliness, Chemometec A/S aims to support its customers in improving their research outcomes and diagnostic capabilities.

What is the P/E ratio of Chemometec A/S 2024?

The Chemometec A/S P/E ratio is 57.18.

What is the P/S ratio of Chemometec A/S 2024?

The Chemometec A/S P/S ratio is 19.11.

What is the Quality Investing of Chemometec A/S?

The Quality Investing for Chemometec A/S is 10/10.

What is the revenue of Chemometec A/S 2024?

The Chemometec A/S revenue is 407.87 M DKK.

How high is the profit of Chemometec A/S 2024?

The Chemometec A/S profit is 136.28 M DKK.

What is the business model of Chemometec A/S

Chemometec A/S is a Danish biotech company that offers innovative solutions and products for cell analysis in the fields of Hematology, Oncology, and Stem Cell Research. Their core product is the NucleoCounter platform, which includes automated cell counters with patented technology for precise counting and sizing of cells. The company serves various customers, including research institutions, clinical labs, hospitals, biotech and pharma companies, and contract research organizations. They aim to provide solutions that help customers achieve their scientific and clinical goals faster, more reliably, and at a lower cost.

What is the Chemometec A/S dividend?

Chemometec A/S pays a dividend of 0 DKK distributed over payouts per year.

How often does Chemometec A/S pay dividends?

The dividend cannot currently be calculated for Chemometec A/S or the company does not pay out a dividend.

What is the Chemometec A/S ISIN?

The ISIN of Chemometec A/S is DK0060055861.

What is the Chemometec A/S WKN?

The WKN of Chemometec A/S is A0MS80.

What is the Chemometec A/S ticker?

The ticker of Chemometec A/S is CHEMM.CO.

How much dividend does Chemometec A/S pay?

Over the past 12 months, Chemometec A/S paid a dividend of 4 DKK . This corresponds to a dividend yield of about 0.89 %. For the coming 12 months, Chemometec A/S is expected to pay a dividend of 1.61 DKK.

What is the dividend yield of Chemometec A/S?

The current dividend yield of Chemometec A/S is 0.89 %.

When does Chemometec A/S pay dividends?

Chemometec A/S pays a quarterly dividend. This is distributed in the months of November, November, November, November.

How secure is the dividend of Chemometec A/S?

Chemometec A/S paid dividends every year for the past 5 years.

What is the dividend of Chemometec A/S?

For the upcoming 12 months, dividends amounting to 1.61 DKK are expected. This corresponds to a dividend yield of 0.36 %.

In which sector is Chemometec A/S located?

Chemometec A/S is assigned to the 'Health' sector.

Wann musste ich die Aktien von Chemometec A/S kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Chemometec A/S from 10/15/2024 amounting to 4 DKK, you needed to have the stock in your portfolio before the ex-date on 10/11/2024.

When did Chemometec A/S pay the last dividend?

The last dividend was paid out on 10/15/2024.

What was the dividend of Chemometec A/S in the year 2023?

In the year 2023, Chemometec A/S distributed 6 DKK as dividends.

In which currency does Chemometec A/S pay out the dividend?

The dividends of Chemometec A/S are distributed in DKK.

All fundamentals about Chemometec A/S

Our stock analysis for Chemometec A/S Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Chemometec A/S Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.